BRAF Mutation in Metastatic Colorectal Cancer

Abstract

To the Editor: We recently found that progression-free survival was shorter among patients with metastatic colorectal cancer treated with chemotherapy, bevacizumab, and cetuximab (CBC regimen) than among patients who received chemotherapy and bevacizumab alone (CB regimen) (Feb. 5 issue).1 Other investigators have found that the efficacy of cetuximab is limited to patients with wild-type–KRAS tumors.2 In a subgroup of 520 patients with available tumor samples, we observed a shorter median progression-free survival among patients with a mutated-KRAS oncogene in the CBC group than among patients with mutated-KRAS tumors who received the CB regimen and among patients with . . .